AR092316A1 - Composiciones - Google Patents

Composiciones

Info

Publication number
AR092316A1
AR092316A1 ARP130101497A ARP130101497A AR092316A1 AR 092316 A1 AR092316 A1 AR 092316A1 AR P130101497 A ARP130101497 A AR P130101497A AR P130101497 A ARP130101497 A AR P130101497A AR 092316 A1 AR092316 A1 AR 092316A1
Authority
AR
Argentina
Prior art keywords
amino acid
tyrosine
cysteine
leucine
arginine
Prior art date
Application number
ARP130101497A
Other languages
English (en)
Original Assignee
Affiris Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Affiris Ag filed Critical Affiris Ag
Publication of AR092316A1 publication Critical patent/AR092316A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/0005Vertebrate antigens
    • A61K39/0007Nervous system antigens; Prions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505Inorganic adjuvants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55555Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55566Emulsions, e.g. Freund's adjuvant, MF59
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/555Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511Organic adjuvants
    • A61K2039/55577Saponins; Quil A; QS21; ISCOMS
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6037Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/60Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031Proteins
    • A61K2039/6081Albumin; Keyhole limpet haemocyanin [KLH]

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Una composición que comprende por lo menos un mimótopo de un epítopo del péptido b amiloide (Ab) para utilizar en la prevención y/o tratamiento de las sinucleinopatías y/o mejora de los síntomas motores y/o cognitivos de las sinucleopatías, donde dicho por lo menos un mimótopo está acoplado o fusionado a una proteína portadora farmacéuticamente aceptable seleccionada entre el grupo que consiste en un mutante no tóxico de la toxina de la difteria, hemocianina de lapa californiana (KLH), toxina de la difteria (DT), toxoide tetánico (TT) y proteína D de Haemophilus influenzae (proteína D). Reivindicación 8: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: X¹X²X³X⁴X⁵X⁶X⁷ donde X¹ es G o un aminoácido con un grupo hidroxi o un aminoácido cargado negativamente, preferentemente glicina (G), ácido glutámico (E), tirosina (Y), Serina (S) o ácido aspártico (D), X² es un aminoácido hidrófobo o un aminoácido cargado positivamente, preferentemente asparagina (N), isoleucina (I), leucina (L), valina (V), lisina (K), triptófano (W), arginina (R), tirosina (Y), fenilalanina (F) o alanina (A), X³ es un aminoácido cargado negativamente, preferentemente ácido aspártico (D) o ácido glutámico (E), X⁴ es un aminoácido aromático o un aminoácido hidrófobo o leucina (L), preferentemente tirosina (Y), fenilalanina (F) o leucina (L), X⁵ es histidina (H), lisina (K), tirosina (Y), fenilalanina (F) o arginina (R), preferentemente histidina (H), fenilalanina (F) o arginina (R), y X⁶ no está presente o serina (S), treonina (T), asparagina (N), glutamina (Q), ácido aspártico (D), ácido glutámico (E), arginina (R), isoleucina (I), lisina (K), tirosina (Y), o glicina (G), preferentemente treonina (T), asparagina (N), ácido aspártico (D), arginina (R), isoleucina (I) o glicina (G), X⁷ no está presente o es cualquier aminoácido, preferentemente prolina (P), tirosina (Y), treonina (T), glutamina (Q), alanina (A), histidina (H) o serina (S); preferentemente EIDYHR, ELDYHR, EVDYHR, DIDYHR, DLDYHR, DVDYHR, Dl-DYRR, DLDYRR, DVDYRR, DKELRI, DWELRI, YREFFI, YREFRI, YAEFRG, EAEFRG, DYEFRG, ELEFRG, DRELRI, DKELKI, DRELKI, GREFRN, EYEFRG, DWEFRDA, SWEFRT, DKELR, SFEFRG, DAEFRWP, DNEFRSP, GSEFRDY, GAEFRFT, SAEFRTQ, SAEFRAT, SWEFRNP, SWEFRLY, SWELRQA, SVEFRYH, SYEFRHH, SQEFRTP, SSEFRVS, DWEFRD, DAELRY, DWELRQ, SLEFRF, GPEFRW, GKEFRT, AYEFRH, DKE(Nle)R, DKE(Nva)R o DKE(Cha)R. Reivindicación 9: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: X¹RX²DX³(X⁴)ₙ(X⁵)ₘ(X⁶)ₒ donde X¹ es isoleucina (I) o valina (V), X² es triptofano (W) o tirosina (Y), X³ es treonina (T), valina (V), alanina (A), metionina (M), glutamina (Q) o glicina (G), X⁴ es prolina (P), alanina (A), tirosina (Y), serina (S), cisteína (C) o glicina (G), X⁵ es prolina (P), leucina (L), glicina (G) o cisteína (C), X⁶ es cisteína (C), n, m y o son, independientemente, 0 ó 1; preferentemente IRWDTP(C), VRWDVYP(C), IRYDAPL(C), IRYDMAG(C), IRWDTSL(C), IRWDQP(C), IRWDG(C) o IRWDGG(C). Reivindicación 10: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: EX¹WHX²X³(X⁴)ₙ(X⁵)ₘ donde X¹ es valina (V), arginina (R) o leucina (L), X² es arginina (R) o ácido glutámico (E), X³ es alanina (A), histidina (H), lisina (K), leucina (L), tirosina (Y) o glicina (G), X⁴ es prolina (P), histidina (H), fenilalanina (E) o glutamina (Q) o cisteína (C), X⁵ es cisteína (C), n y m son, independientemente, 0 ó 1; preferentemente EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C), ELWHRAF(C), ELWHRA(C), EVWHRG(C), EVWHRH(C) y ERWHEK(C), preferentemente EVWHRHQ(C), ERWHEKH(C), EVWHRLQ(C), ELWHRYP(C) o ELWHRAF(C). Reivindicación 12: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: (X¹ᵃ)ₘGX²ᵃX³ᵃX⁴ᵃFX⁵ᵃX⁶ᵃ(X⁷ᵃ)ₙ donde X¹ᵃ es serina (S), alanina (A) o cisteína (C), X²ᵃ es serina (S), treonina (T), ácido glutámico (E), ácido aspártico (D), glutamina (Q) o metionina (M), X³ᵃ es isoleucina (1), tirosina (Y), metionina (M) o leucina (L), X⁴ᵃ es leucina (L), arginina (R), glutamina (Q), triptofano (W), valina (V), histidina (H), tirosina (Y), isoleucina (I), lisina (K) metionina (M) o fenilalanina (F), X⁵ᵃ es alanina (A), fenilalanina (F), histidina (H), asparagina (N), arginina (R), ácido glutámico (E), isoleucina (I), glutamina (Q), ácido aspártico (D), prolina (P) o triptofano (W),glicina (G), X⁶ᵃ es cualquier residuo de aminoácido, X⁷ᵃ es cisteína (C), m y n son, independientemente, 0 ó 1; preferentemente SGEYVFH(C), SGQLKFP(C), SGQIWFR(C), SGEIHFN(C), GQIWFIS(C), GQIIFQS(C), GQIRFDH(C), GEMWFAL(C), GELQFPP(C), GELWFP(C), GEMQFFI(C), GELYFRA(C), GEIRFAL(C), GMIVFPH(C), GEIWFEG(C), GDLKFPL(C), GQILFPV(C), GELFFPK(C), GQIMFPR(C), GSLFFWP(C), GEILFGM(C), GQLKFPF(C), GTIFFRD(C), GQIKFAQ(C), GTLIFHH(C), GEIRFGS(C), GQIQFPL(C), GEIKFDH(C), GEIQFGA(C), GELFFEK(C), GEIRFEL(C), GEIYFER(C), SGEIYFER(C), AGEIYFER(C) o (C)GEIYFER. Reivindicación 13: La composición según cualquiera de las reivindicaciones 1 a 7, donde el por lo menos un mimótopo comprende la secuencia de aminoácidos: (X¹ᵇ)ₘHX²ᵇX³ᵇX⁴ᵇX⁵ᵇFX⁶ᵇ(X⁷ᵇ)ₙ donde X¹ᵇ es serina (S), treonina (T) o cisteína (C), X²ᵇ es glutamina (Q), treonina (T) o metionina (M), X³ᵇ es lisina (K) o arginina (R), X⁴ᵇ es leucina (L), metionina (M), X⁵ᵇ es triptofano (W), tirosina (Y), fenilalanina (F) o isoleucina (1), X⁶ᵇ es asparagina (N), ácido glutámico (E), alanina (A) o cisteína (C), X⁷ᵇ es cisteína (C), n y m son, independientemente, 0 ó 1; preferentemente SHTRLYF(C), HMRLFFN(C), SHQRLWF(C), HQKMIFA(C), HMRMYFE(C), THQRLWF(C) o HQKMIF(C). Reivindicación 16: La composición según cualquiera de las reivindicaciones 1 a 15, donde el por lo menos un mimótopo se selecciona entre el grupo de DKELRI, SWEFRT, SEFKHG, ILFRHG, TLHEFRH, GAEFRFT, DWEFRD, SLEFRF, GREFRN, IRWDTP y HQKMIFA.
ARP130101497A 2012-05-01 2013-05-02 Composiciones AR092316A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP12166316.5A EP2659908A1 (en) 2012-05-01 2012-05-01 Compositions

Publications (1)

Publication Number Publication Date
AR092316A1 true AR092316A1 (es) 2015-04-15

Family

ID=48407469

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP130101497A AR092316A1 (es) 2012-05-01 2013-05-02 Composiciones

Country Status (4)

Country Link
EP (1) EP2659908A1 (es)
AR (1) AR092316A1 (es)
TW (1) TW201345927A (es)
WO (1) WO2013164357A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015165961A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA2946929A1 (en) * 2014-04-29 2015-11-05 Affiris Ag Treatment and prevention of alzheimer's disease (ad)
CA3004498A1 (en) 2015-11-09 2017-05-18 Neil R. Cashman Amyloid beta epitopes and antibodies thereto
KR20180085736A (ko) 2015-11-09 2018-07-27 더 유니버시티 오브 브리티쉬 콜롬비아 아밀로이드 베타 중간-영역 내 에피토프 및 이에 대해 구조적으로 선택성인 항체
JP2019533426A (ja) 2016-07-18 2019-11-21 ザ・ユニバーシティ・オブ・ブリティッシュ・コロンビア アミロイドベータに対する抗体
US20180125920A1 (en) 2016-11-09 2018-05-10 The University Of British Columbia Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions
CN108676072B (zh) * 2018-05-24 2021-05-14 华南理工大学 一种具有抗Aβ42蛋白聚集功能的多肽及其应用与编码该多肽的基因

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0114787B1 (de) 1983-01-25 1991-09-25 Ciba-Geigy Ag Neue Peptidderivate
GB8815795D0 (en) 1988-07-02 1988-08-10 Bkl Extrusions Ltd Glazing bead
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
UA40597C2 (uk) 1992-06-25 2001-08-15 Смітклайн Бічем Байолоджікалс С.А. Вакцинна композиція,спосіб лікування ссавців, що страждають або сприйнятливі до інфекції, спосіб лікування ссавців, що страждають на рак, спосіб одержання вакцинної композиції, композиція ад'ювантів
ES2162139T5 (es) 1993-03-23 2008-05-16 Smithkline Beecham Biologicals S.A. Composiciones de vacuna que contienen monofosforil-lipido a 3-o-desacilado.
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
GB9513261D0 (en) 1995-06-29 1995-09-06 Smithkline Beecham Biolog Vaccines
AUPO517897A0 (en) 1997-02-19 1997-04-11 Csl Limited Chelating immunostimulating complexes
GB9712347D0 (en) 1997-06-14 1997-08-13 Smithkline Beecham Biolog Vaccine
AU1145699A (en) 1997-09-05 1999-03-22 Smithkline Beecham Biologicals (Sa) Oil in water emulsions containing saponins
US6303114B1 (en) 1998-03-05 2001-10-16 The Medical College Of Ohio IL-12 enhancement of immune responses to T-independent antigens
EP1069910A1 (en) 1998-04-09 2001-01-24 GlaxoSmithKline Biologicals S.A. Adjuvant compositions
NZ513935A (en) 1999-02-17 2004-02-27 Csl Ltd Immunogenic complexes and methods relating thereto
KR20020038770A (ko) 1999-09-24 2002-05-23 장 스테판느 애쥬번트로서의 폴리옥시에틸렌 소르비탄 에스테르와옥톡시놀의 조합물의 용도 및 백신과 관련된 이의 용도
CO5200838A1 (es) 1999-09-24 2002-09-27 Smithkline Beecham Corp Vacunas
AU2002357007A1 (en) 2001-11-21 2003-06-10 New York University SYNTHETIC IMMUNOGENIC BUT NON-DEPOSIT-FORMING POLYPEPTIDES AND PEPTIDES HOMOLOGOUS TO AMYLOID Beta, PRION PROTEIN, AMYLIN, Alpha-SYNUCLEIN, OR POLYGLUTAMINE REPEATS FOR INDUCTION OF AN IMMUNE RESPONSE THERETO
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
US8697082B2 (en) 2002-11-01 2014-04-15 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
PT1633189T (pt) 2003-05-19 2017-10-04 Prothena Biosciences Ltd Fragmentos truncados de alfa-sinucleína em doença com corpos de lewy
JPWO2004113535A1 (ja) 2003-06-22 2007-09-20 早出 広司 凝集抑制作用を有するシヌクレイン変異体
AT413946B (de) 2004-07-13 2006-07-15 Mattner Frank Dr Impfstoff gegen die alzheimer-krankheit
AU2005333126A1 (en) 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
EP1781325A2 (en) 2004-07-18 2007-05-09 CSL Limited Immuno stimulating complex and oligonucleotide formulations for inducing enhanced interferon-gamma responses
TWI382019B (zh) 2005-08-19 2013-01-11 Array Biopharma Inc 作為類鐸受體(toll-like receptor)調節劑之胺基二氮雜呯
JP5356228B2 (ja) 2006-07-07 2013-12-04 ギリアード サイエンシーズ, インコーポレイテッド toll様レセプター7の調節因子
PE20091236A1 (es) 2007-11-22 2009-09-16 Astrazeneca Ab Derivados de pirimidina como immunomoduladores de tlr7
JP5380465B2 (ja) 2008-03-03 2014-01-08 アイアールエム・リミテッド・ライアビリティ・カンパニー Tlr活性モジュレーターとしての化合物および組成物
SI2276486T1 (sl) 2008-03-24 2014-01-31 4Sc Discovery Gmbh Novi substituirani imidazokinolini
AT506820B1 (de) 2008-06-12 2011-07-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzine gegen alzheimer-krankheit
AT506819B1 (de) 2008-06-12 2011-06-15 Affiris Forschungs Und Entwicklungs Gmbh Vakzin zur behandlung von alzheimer-krankheit
MX2010013647A (es) 2008-06-12 2011-04-05 Affiris Ag Compuestos para tratar sintomas asociados con la enfermedad de parkinson.
AU2009276403B2 (en) 2008-08-01 2016-03-10 Ventirx Pharmaceuticals, Inc. Toll-like receptor agonist formulations and their use

Also Published As

Publication number Publication date
EP2659908A1 (en) 2013-11-06
TW201345927A (zh) 2013-11-16
WO2013164357A1 (en) 2013-11-07

Similar Documents

Publication Publication Date Title
AR092316A1 (es) Composiciones
ES2531541T3 (es) Agentes de unión del receptor Notch1 y procedimientos de uso de los mismos
NZ712148A (en) Wt1 antigen peptide conjugate vaccine
AR125326A2 (es) Composiciones de neisseria meningitidis y métodos de las mismas
RU2011100125A (ru) Соединения для лечения амилоидозов
RU2011100126A (ru) Применение мимотопов для лечения бетта-амилоидозов
AR105616A1 (es) Proteínas de fusión
HRP20160594T1 (hr) Uporaba mimotopa od alfa-sinuklein epitopa za liječenje bolesti s lewyjevim tijelima
JP2015511603A5 (es)
RU2016140627A (ru) Бета-лактамазы с улучшенными свойствами для лечения
MY159464A (en) Reconstituted surfactant composition containing analogs of surfactant protein b (sp-b) and surfactant protein c (sp-c)
ATE532795T1 (de) Tumor-assoziiertes peptid, welches an unterschiedliche menschliche leukozytenantigene der klasse ii bindet
SI3042917T1 (en) PROTITELES AGAINST N3PGL AMILOID BETA PEPTID AND THEIR APPLICATION
DOP2009000167A (es) Vacuna
MY191490A (en) Vaccine against porcine parvovirus
PE20191711A1 (es) Peptidos y combinaciones de los mismos para el uso en la inmunoterapia contra diversos tipos de cancer
RU2015110981A (ru) Комбинации и их применение
WO2013020722A3 (en) Composition comprising small peptide as amyloid beta mimotope and adjuvant for use as vaccine against alzheimer's disease
AR090439A1 (es) Lipopeptidos antimicrobianos cortos
NZ629843A (en) Identification of channelrhodopsin-2 (chop2) mutations and methods of use
RU2014114506A (ru) Вакцина
AR090917A1 (es) Composiciones
IN2014DN08325A (es)
AR095386A1 (es) Péptidos de kntc2 y vacunas que los contienen
EA201492068A1 (ru) Гидрохлоридная соль пептида и ее применение в комбинации с другими пептидами в иммунотерапии

Legal Events

Date Code Title Description
FB Suspension of granting procedure